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DURATION OF UNTREATED PSYCHOSIS AND NEGATIVE SYMPTOMS - A SYSTEMATIC REVIEW AND 
META-ANALYSIS OF INDIVIDUAL PATIENT DATA
ABSTRACT
BACKGROUND
   Longer duration of untreated psychosis (DUP) is associated with poorer outcome 
in terms of positive symptoms, relapse rate, and time to remission. In contrast, the 
association with negative symptoms is less consistent.
AIMS
   The study had three aims. First, to arrive at a more precise estimate of the corre-
lation between DUP and negative symptoms than previous reviews, by substantially 
increasing the amount of available data. Second, to see whether the strength of this 
correlation attenuated over longer follow-up intervals. Third, to determine whether 
there is a relationship between DUP and changes in negative symptoms.
METHOD 
   Relevant databases were searched for studies published between December 1992 
and March 2009 that reported data on DUP and negative symptoms. We obtained 
individual patient data where possible and calculated summary correlations between 
DUP and negative symptoms for each study at baseline, short and long-term follow-
up. We used multilevel regression analysis to examine whether the effect of DUP on 
negative symptoms was greatest in the early stages of illness. 
RESULTS
   We included 28 non-overlapping studies from the 402 papers detected by the 
search strategy. After contacting the authors we obtained individual patient data from 
16 of these studies involving 3339 participants. The mean DUP was 61.4 weeks 
(SD= 132.7, median DUP= 12.0). Shorter DUP was signifi cantly associated with less 
severe negative symptoms at baseline and also at short (1-2 year) and longer term 
follow-up (5-8 year) (r=0.117, 0.180 and 0.202 respectively, p<.001).The relationship 
between improvement in negative symptoms and DUP was found to be non-linear, 
for example: people with a DUP shorter than 9 months showed substantially greater 
negative symptom reduction than those with a DUP of greater than  9 months.
CONCLUSIONS
   Shorter DUP is associated with less severe negative symptoms at short and long-
term follow up, especially when the DUP is less than 9 months. Since there is no 
effective treatment for negative symptoms, reducing DUP to under 9 months may be 
the best way to ameliorate them. 
KEYWORDS
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   Negative symptoms are a core component of the schizophrenia syndrome and 
are commonly described in terms of fi ve dimensions: blunted affect, alogia, anhe-
donia, avolition and asociality (1-3). Negative symptoms are associated with poor 
functional outcome (4), cognitive defi cits (5), social dysfunction and poor quality of 
life (6-8). Negative symptoms are common: the prevalence in short-term follow-up 
studies (up to 2.5 years) is about 45% (4;9;10), and in longer term studies (7.5-10 
years) 20-30% (11). 
   There is no established treatment for primary negative symptoms (2;12). Pharma-
cological treatments, such as neuroleptics have only a marginal impact on negative 
symptom severity (13). Psychosocial treatments for negative symptoms have no 
substantial evidence base in their favor, although there have been three small but 
promising trials (peer support groups (14), music therapy (15) and body oriented 
psychosocial therapy (16)).
   Pending replication of these studies, it may be that the best way to deal with ne-
gative symptoms is prevention. Many countries have already adopted an early inter-
vention approach to the treatment of psychosis on the basis that there is a proven 
association between duration of untreated psychosis and the long-term severity of 
positive symptoms. A similar association between negative symptoms and outcome 
would support early intervention for negative symptoms (17).
   So far two meta-analyses have examined the correlation between DUP and ne-
gative symptoms (18;19). The fi rst, by Marshall et al. reported an association at 6 
and 12 months but not at baseline and 24 months (18).  The second, by Perkins 
et al. claimed that patients with shorter DUP experienced less negative symptoms 
baseline and at follow-up (19). Whilst making a valuable contribution, both reviews 
share three limitations.  First, neither study provided a precise analysis of the effect 
of DUP at long term follow-up, thus: Marshall et al, did not consider data on negative 
symptoms beyond 24 months and Perkins et al. summarized data of all follow-up 
assessments varying from 3 months to 15 years into one combined effect size. Se-
cond, both studies relied exclusively on published data, which meant that they exclu-
ded a substantial number of studies that collected pertinent data but did not publish 
it in a format that could be used in their analyses. Third, both studies used combined 
correlation coeffi cients calculated by different techniques, for example parametric in 
some studies and non-parametric in others.
   As a consequence of these limitations, neither study was able to consider the na-
ture of the relationship between DUP and negative symptoms. It is now well establis-
hed that there is a non-linear relationship between DUP and positive symptoms (20). 
This means that in a patient with a DUP of less than 12 months, the effect of a DUP 
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reduction of for example 2 months on positive symptoms would be greater  than a 
two month reduction in someone with a DUP of more than 12 months.  It is possible 
therefore that a similar non-linear relationship might exist with negative symptoms, 
with important clinical implications.
   The present study therefore had three aims: (a) to provide a precise estimate of 
the correlation between DUP and negative symptoms by substantially increasing 
the amount of available data contributing to the analysis; (b) to see if the strength of 
any correlation attenuates at longer follow up intervals; (c) to determine whether the 
relationship between DUP and negative symptoms was non-linear.
METHODS
   To overcome the limitations of previous meta-analyses it was necessary to obtain 
a substantial dataset of individual patient data (IPD) from fi rst-episode studies. The 
use of individual patient data is the gold standard for meta-analysis (21;22) and of-
fers a greater resolution of effect size than meta-analyses based on study level data. 
Individual patient data permitted us to reanalyze all the data using the same me-
thod of correlation and to calculate correlations that had not been previously publis-
hed.  We were also able to combine data across studies to explore the relationship 
between DUP and negative symptoms.
SEARCH STRATEGY 
   The search aimed to detect all studies that had examined DUP and negative 
symptoms in fi rst episode psychotic patients, and which were available for review up 
to March 2009. The search included the databases MEDLINE and PUBMED using 
the keywords “DUP” AND “psychosis” OR “schizophrenia” and the combination “du-
ration” AND “untreated” AND “psychosis” OR “schizophrenia”. In addition references 
cited in these papers were examined. 
INCLUSION CRITERIA AND DATA EXTRACTION
   Studies were included if they met two criteria. First, participants had experienced a 
fi rst episode of psychosis defi ned as: schizophrenia, schizoaffective disorder, schizo-
phreniform disorder, delusional disorder, brief psychotic disorder or psychosis NOS, 
according to either the Diagnostic Statistical Manual (DSM-IV) or the International 
Classifi cation of Diseases (ICD-10) classifi cation systems. Second, DUP and nega-
tive symptoms had been measured using a standardized method (which for negative 
symptoms was one of the three commonly used scales in this area, i.e.:  the Positive 
and Negative Symptom Scale (PANSS) (23), the Scale for the Assessment of Ne-
gative Symptoms (SANS) (24), or the Brief Psychiatric Rating Scale (BPRS) (25)). 
   Abstracts were screened independently by two reviewers (N.B. and R.K.), and co-
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pies were obtained of any papers describing potentially eligible studies. Each paper 
was assessed independently by two reviewers and any disagreements resolved by 
discussion with a third reviewer ( L.W.) (for table of included studies see Appendix 1). 
The authors of included studies were contacted and asked to provide anonymized 
individual patient data on: gender, age at onset, DUP, and negative symptom scores 
at baseline and all available follow-up points. 
 ANALYSIS
   We calculated the correlation between DUP and negative symptoms for short and 
long term follow up. We defi ned short-term follow up as between 12 to 24 months 
and long term follow up as 60 to 96 months. Studies of which a spearman correlation 
was published were used for sensitivity analysis.
   In cases where more than one assessment was available for short or long term 
follow up, we used the fi rst assessment. The data were analyzed using a two-step 
approach. First, individual patient data from each study were analyzed using the 
non-parametric Spearman’s Rank Correlation. We choose a non-parametric test be-
cause of the signifi cant positive skew in the distribution of DUP. In the second step, 
a meta-analysis of the aggregated data produced for each study was performed 
using Comprehensive Meta- Analysis in order to summarize the correlations (CMA, 
version 2005, Biostat, Inc, Englewood, NJ, 2005) (26). We used random effect mo-
dels because of great differences between research designs. Correlation data were 
synthesized with Fisher’s z transformation into a single correlation coeffi cient (r) with 
95% confi dence intervals (CI).
   CMA also tests for the heterogeneity of the sample populations using I², a test 
parameter, which evaluates the null hypothesis that all studies are assessing the 
same effect size. I² indicates the percentage of total variation across studies due to 
heterogeneity rather than chance, and ranges from 0% (no heterogeneity) to 100% 
(high heterogeneity). Values for I² of 25%, 50% and 75% are considered to represent 
low, moderate and high heterogeneity respectively (27). 
   A major concern when conducting a meta-analysis is publication bias: studies 
that report relatively large effect sizes are more likely to be published than studies 
with smaller effect sizes. If the included studies are a biased sample of all relevant 
studies, consequently the bias will be refl ected in the mean effect computed by the 
meta-analysis. A funnel plot can be made to examine the publication bias using 
Comprehensive Meta-Analysis (CMA, version 2005, Biostat, Inc, Englewood, NJ, 
2005). 
   We examined the nature of the relationship between DUP and negative symptom 
change using the method developed by Drake (20). We used a multilevel regression 
analysis (XTREG in STATA release 11.0) (28;29) to estimate the magnitude of the 
effect of DUP on negative symptom severity reduction after various periods of follow-
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up with the individuals nested within each study. Subsequently, explanatory varia-
bles (gender and age at onset) were added, as potential confounders. The skewed 
distribution of DUP was corrected by converting DUP to its logarithm (logDUP) thus 
allowing the use of parametric statistics. The change of negative symptoms from 
baseline to follow-up was calculated as a percentage of baseline negative symptom 
severity and added in the multilevel regression analysis as the dependent variable. 
We conducted the analysis for negative symptom change at short and long-term fol-
low up, as defi ned above.
RESULTS 
STUDIES AND PATIENTS
   A total of 402 papers were identifi ed by the search strategy, from which we iden-
tifi ed 28 non-overlapping fi rst episode studies that met inclusion criteria (see Ap-
pendix 1) (20; 30-56). The selected studies included a total of 3998 participants. 
Following written requests, authors of 16 studies submitted their data sets which 
covered a total of 3339 participants. From the 12 studies of which individual patient 
data was not available, 2 studies reported a spearman correlation at short term 
follow-up (1-2 years). Table 1 shows the distribution of DUP, gender and age at on-
set of participants for whom individual patient data were available at baseline. The 
follow-up data of 2 studies were incomplete and therefore only baseline data were 
used in our analysis (43;47). 
   The mean age at onset of participants was 26.0 years (SD=8.9), and the mean 
DUP was 61.4 weeks (SD= 132.7 weeks, median DUP= 12.0 weeks). 59% of the 
participants at baseline were males. Mean age at onset for males was 25.0 years 
(SD=8.6) and for females 27.3 years (SD=9.2). There was no statistically signifi -
cant difference in DUP between male and female participants (61.0 weeks and 61.9 
weeks respectively. 
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From the time the individual first described the onset of any positive sx that 
could be rated as 4 or more on the PANSS until the first effective treatment 
was initiated.
Onset of psychotic sx to first treatment with antipsychotic medication.
Onset of positive psychotic sx (score of ≥4 on any of the positive subscale 
items in the PANSS, these sx must have lasted throughout the day for several 
days or appeared several times a week) until the beginning of treatment with 
antipsychotic medication.
Onset date for the earliest psychotic sx.
First noted psychotic symptoms to presentation to the psychiatric services for 
initiation of adequate treatment of a psychotic illness.  
Occurrence of the first clear psychotic symptom to first psychiatric hospitaliza-
tion.
First continuous (present most of the time) psychotic symptoms to initiation of 
adequate antipsychotic drug treatment.
First psychotic sx until the first contact with psychiatric services. 
First onset of psychotic sx until start of antipsychotic medication (for a 
minimum of 6 weeks). 
Onset of delusions and hallucinations. 
Onset of first psychotic symptoms to the initiation of antipsychotic treatment
Onset of psychosis to initiation of treatment.
Onset of first sx to the initiation of neuroleptic treatment 
Onset of psychotic sx to hospitalization for psychosis or initiation of adequate 
treatment.
Onset of psychotic sx to the time of initiation of continuous antipsychotic 
treatment, plus any periods of psychosis previously experienced and sponta-
neously remitted.
Initial onset of psychosis to treatment
(antipsychotic medication of a dosage that should actually lead to a significant 
response in most patients for a period of time (4 weeks)).
Onset of clear symptoms of psychosis to the initiation of antipsychotic medica-
tions.
Onset of psychosis (first week with sx corresponding to a PANSS score of ≥4 
or on positive subscale items 1, 3, 5 or 6 or on the general subscale item 9) 
until start of adequate treatment (structured treatment with antipsychotic 
medications or hospitalization in a highly staffed psychiatric ward to manage 
psychotic sx,). 
First onset of positive symptoms to index admission
Onset of overt hallucinations or delusions, up to the initiation of treatment with 
antipsychotic medication.
Appearance of at least one psychotic sx until initiation of adequate treatment 
Onset of psychotic sx and the time that treatment was initiated.
Onset of the first positive sx to the first hospitalization. 
Onset of positive symptoms to first admission.
Age of onset of psychosis tp age at initiation of antipsychotic treatment.
Onset of psychotic symptoms to service entry.
First manifestation of any positive psychotic sx to the start of antipsychotic 
treatment.
Onset of psychotic symptoms to the first prescription of neuroleptics for 
psychotic symptoms and the first prescription of neuroleptics for psychosis
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Table 1. Summary of the 16 included first episode studies 
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ASSOCIATION BETWEEN DURATION OF UNTREATED PSYCHOSIS 
AND NEGATIVE SYMPTOMS
   Figure 1 shows a summary of the correlations between DUP and negative symptoms 
at baseline and short (1-2 years) and long-term follow-up (5-8 years). The data show 
a statistically signifi cant positive correlation between DUP and negative symptoms 
at baseline (Fisher’s z= 0.117 95%CI 0.064-0.17, at short-term follow-up (Fisher’s 
z= 0.18 95%CI 0.086-0.274) and at long-term follow-up (Fisher’s z= 0.202 95%CI 
0.137- 0.267). There is no evidence for attenuation in the strength of the association 
with longer follow up. Tests for heterogeneity showed that the studies were low to 
moderately heterogeneous (I²=48% at baseline, 75.9% at short term, 27.3% at long 
term follow-up). As a sensitivity analysis the reported Spearman correlation’s where 
added to the meta-analysis at short term follow-up from the who studies on which 
IPD were not obtained (48;50;61). These two additional studies did not substantially 
alter the reported correlations of heterogeneity statistics (I²=71.8%). 
PREDICTED NEGATIVE SYMPTOM CHANGE 
   2150 patients nested in 12 studies were included in the multilevel analysis to explo-
re for the effect of DUP on negative symptom reduction at short-term follow-up. The 
mean follow-up assessment was 15.5 months (95%CI 15.3-15.7). In the multilevel 
analysis for long-term follow-up, 795 individuals nested in 7 studies were included 
and the mean follow-up assessment was 71.4 months (95%CI 70.2-72.7). 
 
Figures 2. and 3. show the percentage change in negative symptoms predicted by a 
given DUP at short and long-term follow-up respectively.
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Study name Statistics for each study Fisher's Z and 95% CI
Fisher's Standard Lower Upper 
Z error Variance limit limit
Addington (2004) 0,040 0,066 0,004 -0,088 0,168
Barnes (2000) -0,017 0,103 0,011 -0,219 0,185
Chen (2005) -0,057 0,105 0,011 -0,264 0,150
Clarke (2006) -0,029 0,083 0,007 -0,192 0,134
Craig (2000) 0,302 0,054 0,003 0,197 0,407
Cullberg (2002) 0,129 0,089 0,008 -0,045 0,303
Drake (2000) 0,061 0,063 0,004 -0,063 0,185
Gorna (2008) 0,254 0,110 0,012 0,038 0,471
Harris (2005) 0,186 0,056 0,003 0,076 0,297
Malla (2007) 0,145 0,083 0,007 -0,018 0,308
Manchanda (2005) 0,076 0,092 0,008 -0,104 0,257
Melle (2004) 0,122 0,059 0,003 0,007 0,236
Montague (1989) 0,276 0,098 0,010 0,084 0,468
Petersen (2005) 0,053 0,061 0,004 -0,067 0,173
Ucok (2006) 0,063 0,104 0,011 -0,141 0,267
Wunderink (2006) 0,184 0,081 0,007 0,025 0,344
0,117 0,027 0,001 0,064 0,170
-1,00 -0,50 0,00 0,50 1,00
Correlation between DUP and negative symptoms at baseline
Study name Statistics for each study Fisher's Z and 95% CI
Fisher's Standard Lower Upper 
Z error Variance limit limit
Addington (2004) 0,125 0,073 0,005 -0,018 0,267
Barnes (2000) 0,263 0,103 0,011 0,061 0,465
Chen (2000) 0,324 0,105 0,011 0,117 0,530
Craig (2000) -0,062 0,063 0,004 -0,185 0,061
Gorna (2008) 0,175 0,111 0,012 -0,043 0,393
Harris (2005) 0,412 0,056 0,003 0,301 0,522
Manchanda (2005) 0,218 0,092 0,008 0,038 0,399
Melle (2004) 0,227 0,062 0,004 0,105 0,349
Petersen (2005) 0,127 0,048 0,002 0,032 0,222
Ucok (2006) -0,105 0,136 0,019 -0,372 0,161
Wunderink (2006) 0,224 0,092 0,009 0,042 0,405
0,180 0,048 0,002 0,086 0,274
-1,00 -0,50 0,00 0,50 1,00
Correlation between DUP and negative symptoms at short term follow-up 
(1-2 year)
Study name Statistics for each study Fisher's Z and 95% CI
Fisher's Standard Lower Upper 
Z error Variance limit limit
Addington (2004) 0,438 0,146 0,021 0,152 0,724
Clarke (2000) 0,258 0,104 0,011 0,053 0,462
Cullberg (2002) 0,040 0,101 0,010 -0,157 0,237
Gorna (2008) 0,293 0,118 0,014 0,062 0,524
Harris (2005) 0,217 0,056 0,003 0,107 0,328
Petersen (2005) 0,160 0,048 0,002 0,066 0,255
Wunderink (2006) 0,219 0,099 0,010 0,025 0,414
0,202 0,033 0,001 0,137 0,267
-1,00 -0,50 0,00 0,50 1,00
Correlation between DUP and negative symptoms at long term follow-up 
(5-8 year)
Figure 1.Summary of correlations between DUP and negative symptoms at baseline 
and short and long term follow up.
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Figure 2. Predicted change in negative symptoms after short term
















































Figure 3. Predicted change in negative symptoms after longer term
follow-up (5-8 years) against duration of untreated psychosis in weeks (with 95% CIs)




   The review has shown that there is a signifi cant positive association between DUP 
and negative symptoms at: baseline, short (1-2 years) and long-term (5-8 years) 
follow-up. The effect is non-linear, so that a reduction in DUP in someone with a 
shorter DUP (i.e. less than 9 months) has a greater impact on negative symptoms 
than the same reduction in someone with a DUP greater than nine months. These 
fi ndings are in accordance with the fi ndings of the TIPS study and the study of Malla 
and colleagues (54;55), both of which suggested that reduction of DUP may be 
as important for improving the severity of negative symptoms as it is for positive 
symptoms (56). Our fi nding of a non-linear association between DUP and negative 
symptoms is similar to that reported by Drake et al. for total PANSS scores (34) albeit 
in a small sample with a short follow-up.
   The association between a longer DUP and persistence of negative symptoms 
(after 1-2 years) is consistent with the hypothesis that in many cases psychosis is a 
clinical manifestation of a progressive pathological process in which early detection 
and intervention could be effective in ameliorating the course of the disorder. Figure 
2 and 3 suggest that the existence of a critical period of DUP of about 9 months in 
which the association with negative symptoms is particularly strong. This fi nding 
supports arguments for early detection and intervention programs, as other than 
prevention, there is no evidence-based treatment for negative symptoms  (56). Ho-
wever, it is important to emphasize that this analysis does not prove that there is a 
causal association between negative symptoms and DUP. 
   As a result of obtaining individual patient data, this review has substantially incre-
ased the amount of information available for analysis. Consequently, it has extended 
the fi ndings of previous meta-analyses by: providing more precise estimates of the 
correlation between duration of untreated psychosis and negative symptoms, exami-
ning the correlation at both short and long-term follow up; and exploring the linearity 
of the association.  This is of clinical importance because the window of opportunity 
to intervene to improve the prognosis of psychosis is considered to last 3-5 years 
(57).  
   The main limitation of the review is that data were obtained on only 16 of 28 eligible 
studies. The 12 studies not obtained included 659 patients. Three studies reported 
correlations between DUP and negative symptoms at 12 to 24 months of follow-up 
of which 2 were spearman correlations. Adding data of these two studies in the meta 
analysis, they did not substantially alter the reported correlations of heterogeneity 
statistics.
   Hence, the conclusions of the meta-analysis presented here are probably not sub-
stantially compromised by the exclusion of those studies.
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Previous studies have noted considerable variation in fi rst episode psychosis cohorts 
(58), for example in: participant characteristics; instruments to assess symptoms; 
and defi nitions of DUP.  Despite these issues, this analysis detected only a mild to 
moderate degree of  statistical heterogeneity between studies, at a level that was 
not suffi cient to undermine the main fi ndings. We conducted a funnel plot in order to 
test publication bias. The plot shows the presence of symmetry for all analysis. Since 
the sampling error is random, this underpins the idea that there is no substantial 
publication bias.
   In summary, the relationship between DUP and negative symptoms has been 
underestimated, and is in fact strong and persistent. A DUP of less than 9 months 
appears to be a strong predictor of improvement of negative symptoms, while most 
patients with a DUP longer than 9 months show persistent negative symptoms. The 
absence of substantially effective treatments for negative symptoms supports redu-
cing DUP as an important option for ameliorating negative symptoms. 
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